Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jan 31:5:11.
doi: 10.3389/fneur.2014.00011. eCollection 2014.

Mechanisms of levetiracetam in the control of status epilepticus and epilepsy

Laxmikant S Deshpande  1 , Robert J Delorenzo  2
Affiliations
Review

Mechanisms of levetiracetam in the control of status epilepticus and epilepsy

Laxmikant S Deshpande et al. Front Neurol. .

Abstract

Status epilepticus (SE) is a major clinical emergency that is associated with high mortality and morbidity. SE causes significant neuronal injury and survivors are at a greater risk of developing acquired epilepsy and other neurological morbidities, including depression and cognitive deficits. Benzodiazepines and some anticonvulsant agents are drugs of choice for initial SE management. Despite their effectiveness, over 40% of SE cases are refractory to the initial treatment with two or more medications. Thus, there is an unmet need of developing newer anti-SE drugs. Levetiracetam (LEV) is a widely prescribed anti-epileptic drug that has been reported to be used in SE cases, especially in benzodiazepine-resistant SE or where phenytoin cannot be used due to allergic side-effects. Levetiracetam's non-classical anti-epileptic mechanisms of action, favorable pharmacokinetic profile, general lack of central depressant effects, and lower incidence of drug interactions contribute to its use in SE management. This review will focus on LEV's unique mechanism of action that makes it a viable candidate for SE treatment.

Keywords: anti-epileptic; calcium homeostasis; levetiracetam; mechanisms; status epilepticus.

PubMed Disclaimer

References

    1. DeLorenzo RJ. Epidemiology and clinical presentation of status epilepticus. Adv Neurol (2006) 97:199–215 - PubMed
    1. DeLorenzo RJ, Garnett LK, Towne AR, Waterhouse EJ, Boggs JG, Morton L, et al. Comparison of status epilepticus with prolonged seizure episodes lasting from 10 to 29 minutes. Epilepsia (1999) 40:164–910.1111/j.1528-1157.1999.tb02070.x - DOI - PubMed
    1. Lowenstein DH, Bleck T, Macdonald RL. It’s time to revise the definition of status epilepticus. Epilepsia (1999) 40:120–210.1111/j.1528-1157.1999.tb02000.x - DOI - PubMed
    1. Penberthy LT, Towne A, Garnett LK, Perlin JB, DeLorenzo RJ. Estimating the economic burden of status epilepticus to the health care system. Seizure (2005) 14:46–5110.1016/j.seizure.2004.06.001 - DOI - PubMed
    1. DeLorenzo RJ, Kirmani B, Deshpande LS, Jakkampudi V, Towne AR, Waterhouse E, et al. Comparisons of the mortality and clinical presentations of status epilepticus in private practice community and university hospital settings in Richmond, Virginia. Seizure (2009) 18:405–1110.1016/j.seizure.2009.02.005 - DOI - PMC - PubMed